December 1, 2014EuroIntervention
The challenge of valve-in-valve procedures in degenerated Mitroflow bioprostheses and the advantage of using the JenaValve transcatheter heart valve
Key result
Transapical JenaValve valve-in-valve implantation appears feasible and safe at 30 days for degenerated Mitroflow bioprostheses.
- n=2
Why the study?
Is transapical valve-in-valve implantation of the JenaValve THV feasible and safe in patients with degenerated Mitroflow bioprostheses?
Population
2 patients with degenerated Mitroflow bioprostheses who are too ill for conventional repeat open heart surgery
Design
Case_series
Follow-up
30 days
Authors
Discussion
Loading...
Member takes
Implication
Supports initial evaluation in high-risk Mitroflow degeneration; leaves open safety, durability, and generalizability in larger cohorts.
Study Design
Type
Case Report (n=2)
Structured PICO
Is transapical valve-in-valve implantation of the JenaValve THV feasible and safe in patients with degenerated Mitroflow bioprostheses?
P
Population
2 patients with degenerated Mitroflow bioprostheses who underwent transapical valve-in-valve implantation of the JenaValve THV, followed for 30 days.
I
Intervention
Transapical valve-in-valve implantation of the JenaValve transcatheter heart valve (THV)
O
Outcome
Feasibility and safety (survival and clinical condition at 30 days)safety
Transapical valve-in-valve implantation of a JenaValve THV is a feasible alternative for high-risk patients with degenerated Mitroflow bioprostheses, though increased pressure gradients should be expected.
Limitations
- Increased transvalvular gradients were noted in both cases.
Cite This Study
Conradi et al. (2014) conducted a case report in Degenerated Mitroflow bioprostheses (n=2). Transapical valve-in-valve implantation of the JenaValve THV was evaluated on Feasibility and safety (survival and clinical condition at 30 days). Transapical valve-in-valve implantation of the JenaValve THV was successful in two patients with degenerated Mitroflow bioprostheses, with both alive and in good clinical condition at 30 days.